As 2025 winds down, pharmaceutical and controlled substance manufacturers are facing a shifting compliance landscape. Now is the ideal time to prepare for DEA regulatory oversight and enhanced drug diversion controls, and evolving FDA expectations for 2026. At Pharma Compliance Group (PCG), we help clients stay ahead of regulatory trends through expert guidance and proactive risk management.
DEA Compliance: A Growing Priority
The Drug Enforcement Administration (DEA) has increased oversight on controlled substance handling, recordkeeping, and reporting. Now is the perfect time for companies to review their DEA registration renewals, security measures, and ARCOS (Automation of Reports and Consolidated Orders System) submissions. Staying compliant isn’t optional — it’s essential to protecting licenses, reputations, and patient safety.
Broader Pharma Compliance Trends for Late 2025
AI Oversight in Manufacturing: Regulators are emphasizing transparency in automated systems and algorithm-driven quality controls.
Supply Chain Integrity: New DEA and FDA guidance highlight supplier verification and suspicious order monitoring.
Environmental & ESG Accountability: Sustainability and ethical sourcing are now part of global compliance audits.
With year-end audits and 2026 regulatory updates approaching, the end of the year offers the ideal window to strengthen DEA compliance programs, conduct mock inspections, and update GxP training for staff handling controlled substances.
At Pharma Compliance Group, we specialize in DEA regulatory compliance consulting, drug diversion prevention, and comprehensive pharmaceutical regulatory support. Our experts help you identify risks before they become violations — keeping your operations safe, compliant, and audit-ready.
Stay ahead of DEA and pharma regulations with PCG — your trusted compliance partner for 2026 and beyond.